Alten
Note: This is a daily stock update and the information stands true as of 28/01/25, 09:00 CET.
Company update:
FY sales down but slightly better than expected. Lackluster early indications for 2025.
FY24 sales were EUR4,143m, up 2% reported, but down 0.2% organically.
The decline accelerated in Q4 (-2.7% like-for-like). However, after several profit warnings in H2 24, the reported figure came in slightly ahead of expectations.
Initial indications for H1 25 suggest a continued decline, potentially at a higher rate of around 4%.
Expert opinion:
We believe momentum will not improve before H2 2025. The share drop has been massive and the company now trades to more palatable valuation level (PE25 of 12.0x and 109x in 2026). Probably too early to come back on the name in my opinion.
For daily updates, subscribe to our newsletter and for detailed information, reach out to us at sales@alphavalue.eu
Company update:
FY sales down but slightly better than expected. Lackluster early indications for 2025.
FY24 sales were EUR4,143m, up 2% reported, but down 0.2% organically.
The decline accelerated in Q4 (-2.7% like-for-like). However, after several profit warnings in H2 24, the reported figure came in slightly ahead of expectations.
Initial indications for H1 25 suggest a continued decline, potentially at a higher rate of around 4%.
Expert opinion:
We believe momentum will not improve before H2 2025. The share drop has been massive and the company now trades to more palatable valuation level (PE25 of 12.0x and 109x in 2026). Probably too early to come back on the name in my opinion.
For daily updates, subscribe to our newsletter and for detailed information, reach out to us at sales@alphavalue.eu
Subscribe to our blog
Alphavalue Morning Market Tip
Weak Q2 results and FY guidance (marginally) cut but a fat 9.4 % div yield.
